NewsMarkets

Health

Novo Nordisk Drug Outperforms Zepbound in Weight Loss Trial

A new clinical trial shows Novo Nordisk's potential Wegovy successor helped patients lose more weight than Eli Lilly's Zepbound.

1 publisher · 1 article · first seen 28 Sept 2026 · updated 1h ago

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Novo Nordisk's next-gen weight loss drug outperforms Zepbound in new trial The Hill ·

In this story

  • Novo Nordisk
  • Wegovy
  • Zepbound

Related stories